Design Therapeutics, Inc.
Clinical-stage biopharma developing small molecule therapies for genetic diseases.
DSGN | US
Overview
Corporate Details
- ISIN(s):
- US25056L1035
- LEI:
- Country:
- United States of America
- Address:
- 6005 HIDDEN VALLEY ROAD, 92011 CARLSBAD
- Website:
- https://www.designtx.com/
- Sector:
- Manufacturing
Description
Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a new class of small molecule therapies for genetic diseases. The company's proprietary GeneTAC® (Gene Targeted Chimera) platform is used to design therapeutic candidates that target the underlying cause of genetic disorders. These molecules are engineered to modulate gene expression—either increasing or decreasing it as needed—without requiring gene editing. The company's initial focus is on monogenic diseases driven by nucleotide repeat expansions, with programs targeting conditions such as Friedreich ataxia, myotonic dystrophy, Fuchs endothelial corneal dystrophy, and Huntington’s disease. The company aims to develop functional cures for patients with significant unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Design Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Design Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Design Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
